Aquinox Pharma (AQXP) Posts Narrower-than-Expected Q3 Loss

Aquinox Pharma (NASDAQ: AQXP) reported Q3 EPS of ($0.43), $0.02 better than the analyst estimate of ($0.45).

“With positive results from the LEADERSHIP trial, we are advancing towards pivotal trials in bladder pain syndrome/interstitial cystitis (BPS/IC) with AQX-1125,” said Mr. David Main, President and CEO of Aquinox. “Proceeds from our recent public offering are expected to fund our planned first Phase 3 trial and other supportive activities for AQX-1125 in BPS/IC and we are looking forward to our scheduled end-of Phase 2 meeting with the FDA to discuss pivotal trial designs.”

Aquinox has scheduled an end-of-Phase 2 meeting with the U.S. Food and Drug Administration, or FDA, on December 8, 2015 to discuss plans to proceed into pivotal trials with AQX-1125 in BPS/IC.

For earnings history and earnings-related data on Aquinox Pharma (AQXP) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c